Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

This is an interventional treatment trial for Extragonadal Germ Cell Tumor focused on measuring recurrent ovarian germ cell tumor, stage IV ovarian germ cell tumor, ovarian choriocarcinoma, ovarian immature teratoma, ovarian mature teratoma, recurrent malignant testicular germ cell tumor, testicular choriocarcinoma, testicular seminoma, testicular yolk sac tumor, ovarian dysgerminoma, ovarian embryonal carcinoma, ovarian yolk sac tumor, ovarian monodermal and highly specialized teratoma, ovarian polyembryoma, stage III malignant testicular germ cell tumor, ovarian mixed germ cell tumor, testicular choriocarcinoma and embryonal carcinoma, testicular choriocarcinoma and seminoma, testicular choriocarcinoma and teratoma, testicular choriocarcinoma and yolk sac tumor, testicular embryonal carcinoma and seminoma, testicular embryonal carcinoma and teratoma with seminoma, testicular embryonal carcinoma and teratoma, testicular embryonal carcinoma and yolk sac tumor with seminoma, testicular embryonal carcinoma and yolk sac tumor, testicular yolk sac tumor and teratoma with seminoma, testicular yolk sac tumor and teratoma, testicular embryonal carcinoma, recurrent extragonadal non-seminomatous germ cell tumor, recurrent extragonadal seminoma, stage IV extragonadal non-seminomatous germ cell tumor, stage IV extragonadal seminoma, recurrent extragonadal germ cell tumor, testicular immature teratoma, testicular mature teratoma, adult teratoma Read More

DISEASE CHARACTERISTICS:

• Histologically confirmed seminoma or nonseminoma germ cell tumors (GCT)

  • Refractory or relapsed disease
  • Metastatic disease

• Progressive disease after prior cisplatin-based chemotherapy AND meets 1 of the following criteria for salvage therapy:

  • Not a candidate for potentially curative therapy
  • Received prior high-dose chemotherapy regimens
  • Declines potentially curative therapy (mediastinal GCT or primary refractory GCT)

• Measurable disease*, defined as 1 of the following:

  • At least 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
  • Elevation of alpha-fetoprotein > 15 ng/mL and/or elevation of human chorionic gonadotropin > 2.2 mIU/L
• NOTE: *Patients with radiographically measurable disease only must have ≥ 1 site that has not undergone prior irradiation

PATIENT CHARACTERISTICS:

• Karnofsky performance status 70-100%
• Absolute neutrophil count ≥ 1,500/mm³
• Platelet count ≥ 100,000/mm³
• Hemoglobin ≥ 9.0 g/dL
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Bilirubin ≤ 1.5 times ULN
• AST and ALT ≤ 2.5 times ULN (unless elevated liver function abnormalities due to underlying malignancy)
• LVEF ≥ 50% by MUGA
• No grade 3 hemorrhage within the past 4 weeks

• None of the following within the past 6 months:

  • Myocardial infarction
  • Severe or unstable angina
  • Coronary or peripheral artery bypass graft
  • Symptomatic congestive heart failure
  • Cerebrovascular accident or transient ischemic attack
  • Pulmonary embolism
• No prolonged QTc interval (i.e., QTc > 450 msec for males and > 470 msec for females)
• No ongoing cardiac dysrhythmias ≥ grade 2
• No uncontrolled hypertension, defined as blood pressure > 150/100 mm Hg despite optimal therapy
• No active infection
• No other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would preclude study compliance, according to the study investigator

• Not pregnant or nursing

  • Negative sonogram required to exclude pregnancy
• Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• No prior sunitinib malate
• More than 4 weeks since prior major surgery and recovered
• More than 4 weeks since prior radiotherapy and recovered
• Concurrent palliative radiotherapy to metastatic lesion(s) allowed provided ≥ 1 measurable lesion has not been irradiated

• No concurrent therapeutic doses of warfarin

  • Low-dose oral warfarin (up to 2 mg daily) for prophylaxis and treatment or heparin products at prophylactic or treatment doses allowed

• No other concurrent investigational or approved anticancer therapies, including chemotherapy, biologic response modifiers, hormone therapy, or immunologic-based treatment

  • Concurrent participation in supportive care or nontreatment trials (e.g., quality-of-life or laboratory analyses) allowed